PriceTargets.com logo

Gritstone bio - GRTS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.00
  • Forecasted Upside: 54.80%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.23 As of 02/7/2023 01:29 PM ET
▲ +0.05 (1.57%)

This chart shows the closing price for GRTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gritstone bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRTS

Analyst Price Target is $5.00
▲ +54.80% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Gritstone bio in the last 3 months. The average price target is $5.00, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 54.80% upside from the last price of $3.23.

This chart shows the closing price for GRTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Gritstone bio. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/7/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2022HC WainwrightLower TargetBuy$12.00 ➝ $7.00Low
10/30/2022Piper SandlerInitiated CoverageOverweight$6.00Low
8/22/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$2.00Low
5/9/2022HC WainwrightLower Target$15.00 ➝ $12.00High
3/14/2022HC WainwrightLower TargetBuy$24.00 ➝ $15.00High
9/20/2021HC WainwrightReiterated RatingBuy$24.00High
8/10/2021HC WainwrightReiterated RatingBuy$24.00Medium
1/21/2021BTIG ResearchBoost TargetBuy$17.00 ➝ $35.00Medium
1/20/2021HC WainwrightBoost TargetBuy$16.00 ➝ $24.00High
1/20/2021Robert W. BairdDowngradeOutperform ➝ Underperform$8.00High
8/6/2020HC WainwrightReiterated RatingBuy$16.00Low
7/14/2020BTIG ResearchLower TargetPositive ➝ Buy$31.00 ➝ $17.00Low
3/12/2020HC WainwrightReiterated RatingBuyHigh
1/15/2020CowenReiterated RatingBuyMedium
12/12/2019CowenReiterated RatingBuyLow
7/25/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$17.00Medium
5/13/2019CowenReiterated RatingBuyHigh
4/1/2019HC WainwrightReiterated RatingBuy$17.00Medium
3/27/2019Berenberg BankInitiated CoverageBuyMedium
3/14/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$20.00High
3/7/2019HC WainwrightInitiated CoverageBuy ➝ Buy$17.00Low
12/11/2018BTIG ResearchBoost TargetBuy$31.00Low
10/23/2018CowenInitiated CoverageOutperformMedium
10/23/2018BarclaysInitiated CoverageOverweight$25.00Medium
10/23/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$18.00Medium
10/23/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$26.00Medium
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/12/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/11/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/9/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/8/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Gritstone bio logo
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.
Read More

Today's Range

Now: $3.23
Low: $3.14
High: $3.28

50 Day Range

MA: $3.23
Low: $2.58
High: $3.92

52 Week Range

Now: $3.23
Low: $1.71
High: $6.10

Volume

100,328 shs

Average Volume

696,018 shs

Market Capitalization

$269.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Gritstone bio?

The following Wall Street analysts have issued research reports on Gritstone bio in the last twelve months: HC Wainwright, Piper Sandler, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for GRTS.

What is the current price target for Gritstone bio?

3 Wall Street analysts have set twelve-month price targets for Gritstone bio in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 57.2%. HC Wainwright has the highest price target set, predicting GRTS will reach $7.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $2.00 for Gritstone bio in the next year.
View the latest price targets for GRTS.

What is the current consensus analyst rating for Gritstone bio?

Gritstone bio currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GRTS, but not buy more shares or sell existing shares.
View the latest ratings for GRTS.

What other companies compete with Gritstone bio?

Other companies that are similar to Gritstone bio include Acumen Pharmaceuticals, Fennec Pharmaceuticals, ProKidney, Century Therapeutics and Innate Pharma. Learn More about companies similar to Gritstone bio.

How do I contact Gritstone bio's investor relations team?

Gritstone bio's physical mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company's listed phone number is (510) 871-6100 and its investor relations email address is [email protected] The official website for Gritstone bio is www.gritstoneoncology.com. Learn More about contacing Gritstone bio investor relations.